Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Vaxcyte, Inc
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with four additional initial public offerings on 1 October.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Merck’s V114 protected against all 15 targeted serotypes in the first two of 16 Phase III studies, but market leader Pfizer’s 20-valent Prevnar 13 successor is on track for a US FDA filing in late 2020.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- SutroVax, Inc.